OakChart

Genmab ADR

GMABHealthcare·Biotechnology·Denmark·Large·NASD·Nov 11 • 3:08 PM ET

53.30-0.77 (-1.42%)
2026-11-11 21:09 CET
Market cap
33,250.13 USD m
Revenue, TTM
4,295.65 USD m
Net income, TTM
728.39 USD m
Free cash flow, TTM
851.27 USD m
EPS diluted, TTM
1.17
P/E
45.67
Compare

Price

GMAB against its 20, 50 and 200-day averages
2050200beat
30.0040.0050.0060.0014.6M29.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GMABclose 53.3020-day 48.5550-day 40.45200-day 31.3553.3052w high52w low

11.1% under the 52-week high of 59.97 on 28 Oct 2026. 52-week low 23.62 on 3 Jun 2026. Last 15 sessions, 51.8% high to low

Volume 0.68× normal · the line is the 50-bar volume average

Profile

GMAB
52-week range, 82% of the way up
23.6259.97

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Employees3029
IPOJun 01, 2009
Beta0.72
ATR, 14d2.42
Rel volume0.68
Short float1.60%
Insider own1.75%
Inst own18.15%

Snapshot

6 groups

Valuation

Index-
Market Cap32.78B
Enterprise Value36.11B
Income728.39M
Sales4.30B
Book/sh10.30
Cash/sh3.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees3029
IPOJun 01, 2009

Ratios

P/E45.67
Forward P/E32.49
PEG1.54
P/S7.63
P/B5.18
P/C17.62
P/FCF38.50
EV/EBITDA25.46
EV/Sales8.41
Quick Ratio2.43
Current Ratio2.45
Debt/Eq0.82
LT Debt/Eq0.77
Option/ShortYes / Yes

Earnings

EPS (ttm)1.17
EPS next Y1.64
EPS next Q0.23
EPS this Y-18.23%
EPS next Y30.52%
EPS next 5Y21.12%
EPS past 3/5Y9.68% 6.84%
Sales past 3/5Y22.11% 19.27%
EPS Y/Y TTM-50.40%
Sales Y/Y TTM19.61%
EPS Q/Q-14.87%
Sales Q/Q16.55%
EarningsNov 05 AMC
EPS/Sales Surpr.57.70% -0.92%

Ownership

Insider Own1.75%
Insider Trans0.00%
Inst Own18.15%
Inst Trans0.19%
ROA7.30%
ROE12.06%
ROIC6.51%
Gross Margin92.60%
Oper. Margin30.63%
Profit Margin16.96%
SMA209.78%
SMA5031.76%
SMA20070.00%
Trades-

Technical

Shs Outstand614.95M
Shs Float604.19M
Short Float1.60%
Short Ratio2.33
Short Interest9.66M
52W High59.97 -11.12%
52W Low23.62 125.66%
Volatility4.81% 5.45%
ATR (14)2.42
RSI (14)65.22
Beta0.72
Rel Volume0.68
Avg Volume4.14M
Volume2,464,041

Performance

Perf Week-3.30%
Perf Month45.75%
Perf Quarter70.07%
Perf Half Y100.75%
Perf YTD73.05%
Perf Year75.85%
Perf 3Y69.48%
Perf 5Y23.47%
Perf 10Y203.43%
Recom1.57
Target Price63.38
Prev Close54.07
Price53.30
Change %-1.42%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 27, 2026UpgradeJJP MorganNeutral → Overweight
Jul 22, 2026UpgradeTTD CowenHold → Buy$43-19.3%
May 27, 2026InitiatedTTruistBuy$40-25.0%
Apr 22, 2026UpgradeGGoldmanNeutral → Buy
Mar 27, 2026InitiatedWWolfe ResearchOutperform$32-40.0%
Mar 02, 2026InitiatedWWells FargoOverweight$40-25.0%
Feb 17, 2026ResumedMMorgan StanleyEqual-Weight$34-36.2%
Feb 17, 2026ResumedJJefferiesBuy$41.50-22.1%
Sep 23, 2025UpgradeGGuggenheimNeutral → Buy$43-19.3%
Apr 01, 2025DowngradeBBernsteinMkt Perform → Underperform

Peers

Mkt cap
TickerCompanyMkt cap
BNTXBioNTech SE ADR21.64B
INCYIncyte Corp24.87B
REGNRegeneron Pharmaceuticals Inc98.60B
SMMTSummit Therapeutics Inc13.38B
ONCBeOne Medicines Ltd ADR44.25B
EXELExelixis Inc17.14B
ARGXArgen X SE ADR61.26B
HALOHalozyme Therapeutics Inc11.59B
JAZZJazz Pharmaceuticals plc15.87B
ASNDAscendis Pharma A/S16.90B

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Klimovsky Judith V.OfficerNov 10 '26Proposed Sale556.781,265704,327Nov 10 12:45 PM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
AVDEAvantis International Equity ETFAUM: 19.73B
CANCTema Oncology ETFAUM: 217.09M
FTQIFirst Trust Nasdaq BuyWrite Income ETFAUM: 978.65M
LOEVHarding Loevner Intl Dev SelectAUM: 87.93M
APIEActivePassive International Equity ETFAUM: 1.13B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
AADRAdvisorShares Dorsey Wright ADR ETFAUM: 33.73M
FFTYCapForce IBD 50 ETFAUM: 51.15M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.5510.3490.5511,1871,19814
2026Q22026-08-060.4910.3560.4901,1551,11616
2026Q12026-05-070.0830.1560.083896905.7712
2025Q42026-02-170.0720.2810.0461,0581,06613
2025Q32025-11-060.6460.4860.6431,022990.4312
2025Q22025-08-070.5420.3990.554925904.2612
2025Q12025-05-080.3050.2350.305715736.5312
2024Q42025-02-110.8700.3740.853895.8894.7115
2024Q32024-11-060.2870.3080.292803.04827.9815
2024Q22024-08-080.3170.3110.313789.59732.4717
2024Q12024-05-020.2930.1860.294598.08572.0317
2023Q42024-02-140.1400.3130.140675.34671.2116
2023Q32023-11-070.4640.3290.472681.04642.8617
2023Q22023-08-030.3050.2900.301620.99601.1317
2023Q12023-05-100.0500.0940.049418.29404.2614
2022Q42023-02-220.1250.3380.121744.06681.4215

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.4920.4980.510776.3748.29
2020FY1.1811.1781.1041,6531,608
2021FY0.6960.6660.7241,2961,279
2022FY1.1911.4291.1672,0782,032
2023FY0.9531.1040.9582,3782,385
2024FY1.6881.2021.7602,9942,996
2025FY1.5371.7251.5373,7203,706
2026FY-1.257--4,471
2027FY-1.640--5,413
2028FY-2.731--6,900
2029FY-3.146--7,744
2030FY-3.678--8,628

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0912351,2521,2041,292
2026Q4S2026-11-0612351,2491,2041,292
2026Q4S2026-11-0512331,2701,2021,472
2026Q4S2026-10-2812331,2701,2021,472
2026Q4S2026-10-2712231,2651,2021,472
2026Q4S2026-10-2612231,2651,2021,472
2026Q4S2026-10-2312231,2651,2021,472
2026Q4S2026-10-2212321,2671,2021,472
2026Q4S2026-10-2112321,2671,2021,473
2026Q4S2026-10-1612721,2671,2021,473
2026Q4S2026-10-1212721,2641,2021,473
2026Q4S2026-10-0612811,2661,2021,473
2026Q4S2026-10-0512811,2661,2021,473
2026Q4S2026-10-0212811,2641,2021,473

Estimate history

EPS, annual0.270.3760.511.1040.7241.1670.9581.761.5411.1671
Period201720182019202020212022202320242025TTM
EPS, quarterly0.2920.8530.3050.5540.6430.0460.0830.490.548
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual358.68478.828804.4151546.1961348.0682049.1352390.3233121.7573731.3864295.65
Period201720182019202020212022202320242025TTM
Sales, quarterly815.74921.134715.492937.451017.3721057.205899.3161153.3571185.772
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual610.857613.2649.106654.136654.301653.716653.304635.402616.19614.945
Period201720182019202020212022202320242025MRQ
Shares, quarterly635.136635.402635.502615.025615.672616.19613.837597.015614.945
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4,295.653,731.393,121.762,390.322,049.141,348.071,546.20804.41478.83
Cost of Goods Sold Incl. D&A344.94309.95202.7480.24-----
Gross Profit3,977.683,421.442,919.022,310.08-----
Selling, General and Administrative Excl. Other2,635.092,167.611,903.421,538.021,117.45828.68543.18388.12246.47
Research and Development1,875.111,563.771,373.801,078.79755.23636.37449.13337.30212.92
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,315.621,253.831,015.59772.06890.71479.66968.76395.46218.48
Interest Expense377.1161.1917.403.922.972.071.531.050.00
Unusual Expense271.97185.5743.510.005.370.003.36--
Net Income Before Taxes777.451,207.691,328.99817.91981.13633.03902.85428.59255.15
Income Taxes49.06241.74191.43186.45210.92154.96175.25103.8922.13
Consolidated Net Income728.39965.951,137.56631.46770.21478.07727.60324.70233.02
Net Income From Continuing Operations728.39965.951,137.56631.46770.21478.07727.60324.70233.02
Net Income728.39965.951,137.56631.46770.21478.07727.60324.70233.02
EPS (Recurring)1.471.751.810.961.170.721.110.510.38
EPS (Basic, Before Extraordinaries)1.181.551.770.971.180.731.120.520.38
EPS (Diluted)1.171.541.760.961.170.721.100.510.38
EBITDA1,418.671,325.041,075.49819.51931.68519.391,003.02416.30232.36
Non-Operating Income (Expense)110.91200.61374.3049.7798.75155.44-61.0234.1836.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense166.93100.1581.5666.3248.3738.4323.8617.1911.21
Price To Earnings Ratio45.9145.9119.9633.4434.6254.0936.9844.7043.90
Price To Sales Ratio5.185.174.328.7813.6519.3817.3317.6721.19
Gross Margin92.6091.6993.5196.64-----
Operating Margin30.6333.6032.5332.3043.4735.5862.6549.1645.63
Net Margin16.9625.8936.4426.4237.5935.4647.0640.3748.66
Shares Outstanding614.95616.19635.40653.30653.72654.30654.14649.11613.20
Market Capitalization33,250.1333,250.1313,257.4620,798.6527,700.2925,881.3826,595.7914,494.542,020.49

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,185.771,153.36899.321,057.211,017.37937.45715.49921.13
Cost of Goods Sold Incl. D&A114.8883.8865.2480.9457.7457.7742.0348.19
Gross Profit1,070.891,069.48834.08976.27959.63879.68673.46872.94
Selling, General and Administrative Excl. Other630.35663.06608.24733.45502.71514.84485.33559.60
Research and Development449.53458.35441.63525.60355.38368.90359.25380.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income440.54406.42225.83242.82456.92364.85188.13313.34
Interest Expense110.89109.84112.4143.972.999.125.007.72
Unusual Expense9.9931.9545.17184.860.000.000.004.43
Net Income Before Taxes353.63294.5874.2754.96479.82428.69244.17515.13
Income Taxes11.99-7.9921.0823.9880.6388.1749.03-34.75
Consolidated Net Income341.65302.5753.2030.98399.18340.52195.13549.88
Net Income From Continuing Operations341.65302.5753.2030.98399.18340.52195.13549.88
Net Income341.65302.5753.2030.98399.18340.52195.13549.88
EPS (Recurring)0.560.530.130.240.640.550.310.86
EPS (Basic, Before Extraordinaries)0.550.490.090.050.650.550.310.87
EPS (Diluted)0.550.490.080.050.640.550.310.85
EBITDA467.52432.37254.94263.83474.87381.09204.14330.27
Non-Operating Income (Expense)33.9629.966.0240.9725.8872.9761.04213.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense71.6928.8238.3628.0626.4026.0919.5120.75
Price To Earnings Ratio45.9120.5217.2112.9715.1911.6011.0619.96
Price To Sales Ratio5.184.114.385.565.303.753.874.28
Gross Margin90.3192.7392.7592.3494.3293.8494.1394.77
Operating Margin37.1535.2425.1122.9744.9138.9226.2934.02
Net Margin28.8126.235.922.9339.2436.3227.2759.70
Shares Outstanding614.95597.02613.84616.19615.67615.03635.50635.40
Market Capitalization33,250.1316,342.8916,535.6818,972.5818,878.8312,707.4112,443.1313,257.46

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,714.972,930.044,169.173,203.862,956.772,643.051,648.04935.38874.58
Short Term Receivables1,151.98929.10733.07845.89519.55445.80449.15203.27102.69
Inventories18.008.618.450.000.000.000.000.000.00
Other Current Assets---0.000.000.000.000.000.00
Total Current Assets2,884.953,867.754,910.684,049.743,476.323,088.852,097.191,138.65977.26
Net Property, Plant & Equipment280.00262.58243.17189.73149.08120.9862.1924.7518.29
Total Investments and Advances37.0031.6619.8619.0956.73177.6922.380.000.00
Long-Term Note Receivable22.007.229.196.894.133.291.651.471.41
Intangible Assets9,477.842,065.9314.9720.9538.8455.5670.6072.0520.06
Deferred Tax Assets171.00126.0831.4236.1740.3729.1020.8859.2047.89
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets12,872.796,361.235,229.284,322.573,765.453,475.472,274.901,296.121,064.92
Short Term Debt Incl. Current Port. of LT Debt291.0012.7713.3410.629.486.903.910.000.00
Accounts Payable1,068.98483.50341.86246.2753.51194.79126.0348.476.60
Income Tax Payable43.00237.458.000.00-0.0010.9719.45-
Other Current Liabilities24.003.334.894.74176.754.27-0.000.0046.15
Total Current Liabilities1,426.98737.06368.09261.63239.75205.97140.9067.9252.76
Long Term Debt5,134.92130.11100.7775.0655.5045.5323.280.000.00
Provision for Risks Charges0.000.000.000.001.990.660.300.220.19
Deferred Tax Liabilities363.99327.57-------
Other Liabilities100.0070.8276.3170.4774.4680.220.150.280.39
Total Liabilities7,025.881,265.55545.17407.16371.70332.37164.6468.4253.34
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5,846.905,095.674,684.113,915.413,393.753,143.092,110.261,227.701,011.58
Total Shareholders Equity5,846.905,095.674,684.113,915.413,393.753,143.092,110.261,227.701,011.58
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5,846.905,095.674,684.113,915.413,393.753,143.092,110.261,227.701,011.58
Total Liabilities & Stockholders Equity12,872.796,361.235,229.284,322.573,765.453,475.472,274.901,296.121,064.92
Book Value Per Share9.498.027.175.995.194.803.252.001.66
Tangible Book Value Per Share-5.894.777.155.965.134.723.141.881.62
Full-Time Employees3,0292,6822,2041,6601,212781548377257
Price to Book Ratio5.252.774.717.877.638.466.878.2311.65
Return on Assets10.0419.6313.1919.0513.2025.3118.1919.7418.51
Return on Equity17.6523.2614.6521.0814.6327.7019.4620.8119.73
Return on Invested Capital8.8021.7713.2019.3013.8622.8215.2218.9816.54
Quick Ratio2.015.2413.3215.4814.5015.0014.8816.7718.52
Current Ratio2.025.2513.3415.4814.5015.0014.8816.7718.52

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income777.331,207.691,328.99817.91981.13633.03902.85428.59255.15
Depreciation103.0571.2259.8942.8051.1439.4239.6120.8413.87
Other Funds (Non Cash)101.26-309.95-149.8115.96-217.56-194.06-109.65-68.06-7.98
Funds from Operations975.65963.941,234.00873.19812.59476.48832.81381.37261.03
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-100.36225.69-107.03197.62-259.94-122.38150.93-182.59-100.41
Cash from Operating Activities875.291,189.631,126.971,070.81552.65354.10983.75198.78160.62
Capital Expenditures-32.01-55.17-44.09-54.56-44.78-40.05-46.95-16.64-75.56
Net Assets From Acquisitions-7,237.08-7,237.08-1,775.950.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments1,664.101,631.98383.29-131.46-345.27-112.68-312.57-280.63-205.80
Purchase of Investments-40.14-998.05-1,252.42-1,582.57-1,370.05-2,481.90-1,898.38-871.27-557.35
Sale Or Maturity of Investments1,704.232,630.031,635.711,451.111,024.782,369.211,585.80590.64351.55
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-5,604.99-5,660.27-1,436.74-186.01-390.05-152.73-359.52-297.27-281.36
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-72.59-408.25-543.83-59.78-88.72-49.5921.41554.67-11.22
Repurchase of Common Pref Stock-95.61-431.32-562.54-81.83-128.27-71.040.000.00-23.14
Sale of Common Pref Stock23.0123.0718.7122.0539.5621.4621.41554.6711.91
Proceedsfrom Stock Options0.000.000.000.000.000.000.00544.920.05
Issuance or Reduction of Debt, Net-5,243.000.000.000.000.00--4.650.00
Change in Long Term Debt-0.000.000.000.000.00--4.650.00
Issuance of Long Term Debt-0.000.000.000.000.00--0.00
Reduction of Long Term Debt-0.000.000.000.000.00--4.650.00
Net Financing Active Other Cash Flow-26.00-18.06-15.81-14.94-12.43-7.95-3.82-1.350.00
Other Financing Activities Uses-26.00-18.06-15.81-14.94-12.43-7.95-3.82-1.350.00
Cash from Financing Activities4,842.274,803.66-568.34-87.93-111.46-66.7510.86548.67-11.22
Exchange Rate Effect-14.023.01151.69-75.1681.09135.09-68.052.403.01
Net Change in Cash98.54336.03-726.42721.71132.23269.71567.04452.58-128.94
Free Cash Flow851.271,152.521,099.851,017.71507.87314.05936.80186.94149.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow26.1516.7512.2620.6255.0883.2028.6076.0267.97
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,859.971,502.981,520.981,714.973,410.982,899.06
Short Term Receivables1,297.9868.001,030.981,151.981,045.99998.02
Inventories30.0018.0021.0018.0014.0013.00
Other Current Assets-1,211.98----
Total Current Assets3,187.952,800.962,572.962,884.954,470.973,910.08
Net Property, Plant & Equipment314.00254.00265.00280.00266.00277.01
Total Investments and Advances39.0036.0040.0037.0036.0035.00
Intangible Assets9,196.879,226.889,302.859,477.842,102.992,107.05
Deferred Tax Assets173.00173.00173.00171.00127.00127.00
Other Assets25.0024.000.000.009.000.00
Total Assets12,935.8112,514.8412,375.8012,872.797,020.966,464.14
Short Term Debt Incl. Current Port. of LT Debt347.99312.00293.00291.0016.0016.00
Accounts Payable931.99806.99860.991,068.98602.00567.01
Income Tax Payable0.000.000.0043.00120.0040.00
Other Current Liabilities19.0021.0024.0024.003.006.00
Total Current Liabilities1,298.981,139.991,177.981,426.98741.00629.01
Long Term Debt4,849.934,960.945,057.925,134.92126.00132.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities364.99364.00364.99363.99330.00330.01
Other Liabilities89.0093.0093.00100.0073.0071.00
Total Liabilities6,602.906,557.926,693.897,025.881,269.991,162.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6,332.915,956.925,681.915,846.905,750.975,302.11
Total Shareholders Equity6,332.915,956.925,681.915,846.905,750.975,302.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6,332.915,956.925,681.915,846.905,750.975,302.11
Total Liabilities & Stockholders Equity12,935.8112,514.8412,375.8012,872.797,020.966,464.14
Book Value Per Share10.309.989.269.499.348.62
Tangible Book Value Per Share-4.66-5.48-5.90-5.895.935.20
Full-Time Employees3,2443,1193,0883,0292,6812,639
Price to Book Ratio5.252.972.833.303.562.48
Return on Assets7.308.288.6910.0422.9121.17
Return on Equity12.0613.9615.0117.6528.2026.08
Return on Invested Capital3.062.770.500.286.796.27
Quick Ratio2.432.442.172.016.016.20
Current Ratio2.452.462.182.026.036.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income353.97295.1074.2754.00481.36428.16
Depreciation26.9825.9529.1121.0117.9516.24
Other Funds (Non Cash)115.05-2.0415.06-26.8036.38-273.50
Funds from Operations494.00318.01116.4347.22534.70169.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital26.22-266.96-113.42253.802.13-105.29
Cash from Operating Activities520.2151.043.01301.02536.8264.59
Capital Expenditures-11.00-2.99-5.02-13.00-1.85-10.30
Net Assets From Acquisitions0.000.000.00-7,237.080.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments2.005.02-4.011,661.10-52.3036.19
Purchase of Investments-1.000.01-4.01-35.13-386.35-304.38
Sale Or Maturity of Investments3.005.010.001,696.23334.04340.57
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-9.002.03-9.03-5,588.98-54.1525.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock13.061.25-94.357.44-13.50-403.19
Repurchase of Common Pref Stock0.050.26-96.360.44-22.51-409.24
Sale of Common Pref Stock13.001.002.017.019.016.06
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-163.01-63.89-63.230.000.000.00
Change in Long Term Debt---0.00--
Issuance of Long Term Debt---0.00--
Reduction of Long Term Debt---0.00--
Net Financing Active Other Cash Flow0.01-8.97-14.05-2.99-0.95-2.10
Other Financing Activities Uses0.01-8.97-14.05-2.99-0.95-2.10
Cash from Financing Activities-150.93-74.60-177.655,245.45-19.45-409.34
Exchange Rate Effect-3.004.03-11.04-4.024.00-4.98
Net Change in Cash357.28-17.49-194.72-46.53467.22-323.83
Free Cash Flow516.2149.05-2.01288.00534.9054.42
Price to Free Cash Flow26.1519.4919.5717.9715.2412.64

Revenue breakdown

Pharmaceutical Preparations2024: 3.12B 2025: 3.72B
Denmark2024: 2.87B 2025: 3.33B
Japan2024: 122.00M 2025: 213.00M
Netherlands2025: 1.00M
United States2024: 131.00M 2025: 180.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.60%9.7M604.2M3.92M
2026-10-151.12%6.6M587.1M2.83M
2026-09-301.03%6.1M587.1M2.39M
2026-09-150.84%4.9M587.1M2.21M
2026-08-311.16%6.8M586.6M2.19M
2026-08-141.30%7.6M586.6M2.07M
2026-07-311.24%7.4M593.9M1.97M
2026-07-151.28%7.6M591.9M1.98M
2026-06-301.41%8.3M591.9M1.82M
2026-06-151.45%8.6M591.8M1.79M
2026-05-291.70%10.0M591.8M1.81M
2026-05-151.72%10.2M591.8M1.78M
2026-04-301.43%8.5M594.9M1.63M
2026-04-151.29%7.9M616.3M1.72M
2026-03-311.39%8.6M616.3M1.76M
2026-03-131.44%8.9M616.3M1.73M
2026-02-271.41%8.7M616.3M1.71M
2026-02-131.28%7.9M616.2M1.60M
2026-01-301.37%8.4M616.0M1.73M
2026-01-151.61%9.9M616.0M1.83M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5038.8042.0026.207.1241500.000.993-0.0400.002
call15.0036.3039.4023.706.1041500.000.992-0.0400.002
call17.5033.9037.7011.336.3884.000.000.991-0.0400.002
call20.0031.3035.1018.805.5982130.000.990-0.0400.002
call22.5028.8032.2032.504.6257950.000.989-0.0400.002
call25.0026.4029.7014.204.1412400.000.987-0.0390.003
call30.0021.3024.6025.503.2308770.000.984-0.0390.003
call35.0017.9019.6018.102.5372,4470.000.979-0.0380.004
call40.0011.9014.5014.301.8662,5140.000.971-0.0360.005
call45.006.409.608.681.3571,1220.000.943-0.0430.009
call50.003.303.903.800.5408,2898.000.832-0.0570.021
call55.000.700.800.750.4391,60650.000.361-0.0890.031
call60.000.100.150.140.5196,0531890.079-0.0360.012
call65.000.050.100.070.7129,4691460.043-0.0310.008
call70.000.000.050.050.8273,7350.000.021-0.0190.004
call75.000.002.150.051.00143.000.000.018-0.0200.004
call80.000.000.250.051.0651110.000.016-0.0190.003
put12.500.002.150.004.2910.000.00-0.007-0.0380.002
put15.000.002.150.603.7896.000.00-0.008-0.0380.002
put17.500.002.150.033.35810.000.00-0.009-0.0370.002
put20.000.002.150.953.01116.000.00-0.010-0.0380.002
put22.500.002.150.802.66932.000.00-0.011-0.0370.002
put25.000.002.150.152.3741,6360.00-0.013-0.0370.003
put30.000.002.150.031.8562,0470.00-0.016-0.0350.003
put35.000.000.800.031.4041,3110.00-0.021-0.0330.004
put40.000.000.100.051.0066220.00-0.028-0.0290.006
put45.000.000.150.050.7215050.00-0.072-0.0450.011
put50.000.200.300.250.4272,46941.00-0.168-0.0520.021
put55.002.102.953.000.6061,2756.00-0.636-0.0830.031
put60.006.507.206.000.7673430.00-0.920-0.0300.012
put65.0011.4013.7010.001.7198.000.00-0.957-0.0230.008
put70.0015.5018.700.002.0340.000.00-0.979-0.0120.004
put75.0019.8023.700.002.3160.000.00-0.982-0.0120.004
put80.0024.6028.700.002.5670.000.00-0.985-0.0120.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-10-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-28SEC
2026-10-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-23SEC
2026-10-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-13SEC
2026-10-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-07SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-05SEC
2026-10-05SCHEDULE 13GSEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-02SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-15SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-17SEC
2026-06-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-16SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-11SEC
2026-05-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-29SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-13SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Paradigm Biocapital Advisors LP2.21%
Orbis Allan Gray Ltd1.91%
ALLIANCEBERNSTEIN L.P.1.45%
DEERFIELD MANAGEMENT COMPANY, L.P.1.15%
Deep Track Capital, LP0.95%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP0.84%
BlackRock, Inc.0.79%
Sofinnova Investments, Inc.0.68%
RENAISSANCE TECHNOLOGIES LLC0.59%
TWO SIGMA INVESTMENTS, LP0.59%

Funds

Fund% owned
iShares Biotechnology ETF0.62%
First Trust NYSE Arca Biotechnology Index Fund0.45%
AB LARGE CAP GROWTH FUND INC0.28%
Avantis International Equity ETF0.09%
Federated Hermes Kaufmann Fund0.09%
Federated Hermes Kaufmann Small Cap Fund0.06%
Federated Hermes International Leaders Fund0.06%
Tax-Managed U.S. Large Cap Fund0.06%
Baird Chautauqua International Growth Fund0.03%
Tema Oncology ETF0.03%

OakChart. GMAB. Cached 15 minutes.